Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 7 of 100 as at 8 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores AIxCrypto Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Value (4): The shares cost a lot relative to the profits and assets behind them.
The rank is the raw material. Whether the rules would actually own AIxCrypto Holdings, Inc. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on AIXC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 71% of US stocks
Cheaper than 33% of US stocks
Cheaper than 88% of US stocks
Cheaper than 59% of US stocks
Higher than 9% of US stocks
Higher than 30% of US stocks
Higher than 6% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIXC appears on the weeks it earns a place.
Seeking Alpha published the transcript of AIxCrypto Holdings, Inc.'s (AIXC) Q2 2026 earnings call. The item is a transcript release documenting the company's quarterly earnings conference call.
Why it matters — An AIXC watcher would care because the earnings call transcript provides the official record of the company's Q2 2026 results and management commentary.
AIxCrypto Holdings reported Q2 2026 results, highlighted by the June 22 launch of RoboShare, an on-demand robot-sharing marketplace, which was subsequently designated the company's top operating priority for the second half of 2026. Total operating expenses fell 32% sequentially to $2,959,325, current liabilities declined 48%, no new shares were issued during the quarter, and the $12.0 million Faraday Future securities investment was completed in April 2026.
Why it matters — The launch of RoboShare as the company's top priority and meaningful cost reductions mark AIXC's shift from strategic planning into focused execution, while its stable share count and improved balance-sheet metrics may draw attention from watchers tracking the company's progress.
AIxCrypto Holdings, Inc. announced it will hold a conference call to discuss its financial results for the second quarter ended June 30, 2026, on Friday, Aug. 7, 2026, at 4:30 PM Pacific Time. The company said it invites stockholders to submit questions in advance of the call.
Why it matters — The announcement gives AIXC watchers the date and logistics for the upcoming earnings call, where the company will report its second-quarter financial results.
As at 8 Aug 2026, AIxCrypto Holdings, Inc. ranks 7 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No analyst covering AIxCrypto Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIXC are extrapolating price history, which says nothing about the business.
AIxCrypto Holdings, Inc. returned -53.1% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Qualigen Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases.
The most recent item we track (Seeking Alpha, 8 Aug 2026): "AIxCrypto Holdings, Inc. (AIXC) Q2 2026 Earnings Call Transcript". Seeking Alpha published the transcript of AIxCrypto Holdings, Inc.'s (AIXC) Q2 2026 earnings call. The item is a transcript release documenting the company's quarterly earnings conference call.
Qualigen Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. Its pipeline includes lead candidate QN-302, an investigational small molecule G-quadruplex-selective transcription inhibitor in Phase 1 clinical trials for pancreatic cancer and other solid tumors. The company is also advancing Pan-RAS in preclinical stages for advanced solid tumors, along with other programs such as QN-247, an oligonucleotide-based drug for nucleolin-expressing cancers; QN-165 for broad-spectrum infectious diseases; RAS-F, a small-molecule inhibitor targeting RAS mutations; and STARS, a selective target antigen removal system to eliminate circulating tumor cells, viruses, and immune checkpoints. Additionally, it offers FastPack, a rapid onsite immunoassay testing system leveraging proprietary nanoparticle technology. Qualigen Therapeutics Inc. targets unmet needs in oncology and infectious disease markets, aiming to deliver innovative treatments through advanced drug candidates and diagnostic tools. Founded in 1996 and headquartered in Carlsbad, California, the company operates in the competitive biopharmaceutical sector with a focus on clinical development and commercialization.
CEO Mr. Jiawei Wang · 10 employees · United States · https://www.aixcrypto.ai